An NCI-designated Comprehensive Cancer Center
800-826-4673
800-826-4673
An NCI-designated Comprehensive Cancer Center
Main Menu
white fone icon800-826-HOPE (4673)
ES Demo_HopefulIcon_01082019Join HOPEFUL
Find a Doctor Back
Larry Kwak Video
play icon

Larry W. Kwak, M.D., Ph.D.

Hematologist - Oncologist; Dr. Michael Friedman Professor in Translational Medicine
Clinical Expertise
Research Focus
  • Immunology
  • Cancer vaccines
Appointments
Vice President and Deputy Director, Comprehensive Cancer Center; Director, Toni Stephenson Lymphoma Center; Professor, Department of Hematology & Hematopoietic Cell Transplantation
800-826-4673
Request an Appointment Online
Biography Menu

Clinical Teams

  • Hematology & Hematopoietic Cell Transplantation
  • Lymphoma
Larry W. Kwak, M.D., Ph.D., is a world-renowned physician and scientist who has pioneered breakthrough innovations in immunology and cancer vaccines. He joined City of Hope in April 2015, following a decade of leadership in lymphoma and myeloma research and treatment at M.D. Anderson Cancer Center in Houston.
 
Named one of TIME magazine's "100 Most Influential People" in 2010, Dr. Kwak is the deputy director of City of Hope's comprehensive cancer center, director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine.
 
Passionate about harnessing the body's immune system to battle cancer, Dr. Kwak's interest in the field was sparked by a high school mentor and has continued for nearly three decades. He takes special pride in his ability to rapidly translate basic research into human clinical trials, making him an ideal fit for the City of Hope environment.
 

Locations

Duarte
Duarte

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

626-256-4673 | Learn More
Education

Board Certifications

  • 1989 - American Board of Internal Medicine, Subspecialty Medical Oncology
  • 1987 - American Board of Internal Medicine

Degrees

  • 1984 – Ph.D., Tumor Cell Biology, Northwestern University Graduate School, Evanston, IL 1982 – B.S., M.D., Honors Program, Northwestern University Medical School, Chicago, IL 1979 – B.S., Medical Sciences, Northwestern University, Evanston, IL

Fellowship

  • 1987 – 1991, Fellow, Medical Oncology, Stanford University School of Medicine, Stanford, CA
  • 1983 – 1984, Fellow, Tumor Cell Biology, Northwestern University Medical School, Chicago, IL

Residency

  • 1985 – 1987, Resident, Internal Medicine, Stanford University Medical Center, Stanford, CA

Internship

  • 1984 – 1985, Intern, Internal Medicine, Stanford University Medical Center, Stanford, CA
Research

Lab Members

Hong Qin
Assistant Research Professor
Awards
  • 2016, Ho-Am Prize in Medicine, Seoul, South Korea
  • 2016, Elected to Association of American Physicians
  • 2011, Chang-Yul Oh Memorial Award, Korean American Medical Association
  • 2010, TIME 100 (Named by TIME magazine as one of the 100 most influential persons in the world)
  • 2010, Team Science Award recipient, International Society for the Biological Therapy of Cancer
  • 2003, NCI Technology Transfer Award, Center for Cancer Research
  • 2003, Elected to American Society for Clinical Investigation
  • 2002, European Academy of Sciences
  • 2000, Asian and Pacific Islander-American Organization Outstanding Scientific Achievement Award, National Institutes of Health
  • 1989, Young Investigator Award, American Society of Clinical Oncology
  • 1984, Physicians Research Training Fellowship, American Cancer Society, New York
  • 1983, Lady Tata Memorial Trust Postgraduate Award, London, England
Memberships
  • 2012 - Education Committee, American Association for Cancer Research, Chicago, IL
  • 2012 – present, Trust Committee, Society for Immunotherapy of Cancer, Milwaukee, WI
  • 2007 – present, Panel of Scientific Advisors, Lymphoma Research Foundation, USA
In The News
An Expert's Voice
See All
Larry Kwak

CAR T cell therapy targeting new receptor proves effective for relapsed CAR T patients

City of Hope News

First chimeric antigen receptor (CAR) T cell therapy targeting B cell-activating factor receptor (BAFF-R) eradicates blood cancers that relapsed after CD19 CAR T therapies

red and white blood cells illustration stock - large hi res

City of Hope investigators present breakthrough research at 60th American Society of Hematology meeting

City of Hope Comprehensive Cancer Center
CONNECT WITH US
CONNECT WITH US
City of Hope Comprehensive Cancer Center
US News badge 2019-20- footer
NCI CCC logo GIF
NCCN Logo Black
© 2020 CITY OF HOPE and the City of Hope logo are registered trademarks of City of Hope.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.